We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · March 17, 2021

Umbralisib in Patients With Relapsed or Refractory Indolent Lymphoma

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
J. Clin. Oncol 2021 Mar 08;[EPub Ahead of Print], NH Fowler, F Samaniego, W Jurczak, N Ghosh, E Derenzini, JA Reeves, W Knopińska-Posłuszny, CY Cheah, T Phillips, E Lech-Maranda, BD Cheson, PF Caimi, S Grosicki, LA Leslie, JC Chavez, G Fonseca, S Babu, DJ Hodson, SH Shao, JM Burke, JP Sharman, JY Law, JM Pagel, HP Miskin, P Sportelli, OA O'Connor, MS Weiss, PL Zinzani

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading